I'm just guessing, but I think this acquisition is a way for them to receive non-dilutive financing to develop another asset. Back in 2010, the DoD gave Lonza $18M to develop this asset. Regenicin then licensed it from Lonza to develop for commercialization. If the DoD is still interested in this, perhaps there's more funding coming.

http://www.prnewswire.com/news-releases/depar...62559.html